Microbial diversity in adenine-induced renal failure mice.

The composition of gut microbiota is changed with the progression of chronic kidney disease (CKD). Inhibition of intestinal sodium/glucose co-transporter (SGLT) SGLT altered gut microbiota. The aim of this study was to examine the effect of a SGLT1 inhibitor on the microbial diversity in an adenine-induced renal failure mice. To analyze the effect of the SGLT1 inhibitor on the intestinal microbiome, we performed the fecal 16S rRNA gene sequencing using V1-V2 variable region with Next Generation Sequencer. As a result, the principal coordinates analysis of the microbiome and whole gut microbial composition analysis were performed between control and the treated group with renal failure. In addition, at the genus level, some major taxa reduced in the renal failure mice were altered by SGLT1 inhibitor. These data suggested that SGLT1 inhibition modified of the gut microbiota, providing a novel and potential therapeutic tool for CKD patients.

肠道微生物群的组成会随慢性肾脏病（chronic kidney disease, CKD）的进展发生改变。抑制肠道钠-葡萄糖协同转运蛋白（intestinal sodium/glucose co-transporter, SGLT）可调控肠道微生物群结构。本研究旨在探究SGLT1抑制剂对腺嘌呤诱导肾衰竭小鼠肠道微生物多样性的影响。为分析SGLT1抑制剂对肠道微生物组的作用效果，本研究采用下一代测序仪，针对粪便样本的16S rRNA基因V1-V2可变区开展测序分析。结果显示，本研究对对照组与肾衰竭模型给药组的微生物组进行了主坐标分析及全肠道微生物组成分析。此外，在属水平上，肾衰竭模型小鼠体内原本减少的部分主要微生物类群，可因SGLT1抑制剂的干预发生显著改变。上述数据表明，SGLT1抑制可重塑肠道微生物群结构，为慢性肾脏病患者提供了一种新型潜在治疗策略。